Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment
Anticancer Research · 2026
DOI: 10.21873/anticanres.17952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yoshihiko Sugino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ichinomiya Municipal Hospital, Ichinomiya, Japan; yoshihiko-s@yaku138.com. Hauptthemen laut MEDLINE: Bevacizumab, Breast Neoplasms, Hypertension, Antineoplastic Combined Chemotherapy Protocols.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ichinomiya Municipal Hospital, Ichinomiya, Japan; yoshihiko-s@yaku138.com.
- Department of Pharmacy, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
- Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan saito-yo@hus.ac.jp.
Zitieren
APA
Sugino, Y., Sakurada, H., Baba, M., & Saito, Y. (2026). Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment. Anticancer Research. https://doi.org/10.21873/anticanres.17952
Vancouver
Sugino Y, Sakurada H, Baba M, Saito Y. Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment. Anticancer Research. 2026. doi:10.21873/anticanres.17952
BibTeX
@article{Sugino2026,
author = {Sugino, Yoshihiko and Sakurada, Hiroaki and Baba, Misako and Saito, Yoshitaka},
title = {Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.17952}
}
EUVIMED